You are here

J Cell Biochem DOI:10.1002/jcb.29137

Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro.

Publication TypeJournal Article
Year of Publication2020
AuthorsAlgate, K, Haynes, D, Fitzsimmons, T, Romeo, O, Wagner, F, Holson, E, Reid, R, Fairlie, D, Bartold, P, Cantley, M
JournalJ Cell Biochem
Date Published2020 Jan

The regulation of epigenetic factors is an emerging therapeutic target of immune function in a variety of osteolytic pathologies. Histone deacetylases (HDAC) modify core histone proteins and transcriptional processes, in addition to nonhistone protein activity. The activated immune response in rheumatoid arthritis, periodontitis, and prosthetic implant particle release stimulates the catabolic activity of osteoclasts. In this study, we investigated the effects of novel therapeutic agents targeting HDAC isozymes (HDAC 1, 2, and 5), previously shown to be upregulated in inflammatory bone disorders, in cytokine-stimulated human monocytes and osteoclasts in vitro. Inhibiting HDAC 1 and 2 significantly reduced gene expression of IL-1β, TNF, MCP-1, and MIP-1α in TNF-stimulated monocytes, while suppressing secretions of IL-1β, IL-10, INF-γ, and MCP-1 (P 


Alternate JournalJ. Cell. Biochem.
PubMed ID31222845
Grant List1057835 / / National Health and Medical Research Council /
1070880 / / National Health and Medical Research Council (NHMRC) Early Career Research Fellowship /